Outsourcing has been shown as the most effective approach to cut down cost on clinical development. A study published in 2006 has shown that compared to internal drug development, up to $3.6 million could be saved with complete outsourcing. Pharmas and biotech have been increasingly adopting outsourcing and offshoring to conduct clinical trials. In particular, Asia has become second to Eastern Europe among the emerging regions for sponsored global trials. Taiwan has stood out as the most active locations for multi-national trials. According to data from US-based trial register, the number of trials in Taiwan has reached 2671, ranking it 3rd after China and Korea.